Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid

被引:32
|
作者
Hestvik, A. L. K. [1 ]
Skorstad, G. [2 ]
Price, D. A. [3 ]
Vartdal, F. [1 ]
Holmoy, T. [1 ,2 ]
机构
[1] Rikshosp Radiumhosp, Inst Immunol, Fac Med, Oslo, Norway
[2] Ullevaal Univ Hosp, Dept Neurol, Oslo, Norway
[3] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DU, England
关键词
multiple sclerosis; immunology; glatiramer acetate; disease modifying therapies;
D O I
10.1177/1352458508089411
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Glatiramer acetate (GA) is believed to induce GA-reactive T cells that secrete anti-inflammatory cytokines at the site of inflammation in multiple sclerosis (MS). However, GA-reactive T cells have not been established from the intrathecal compartment of MS patients, and intrathecal T cells may differ from T cells in blood. Here, we compared the phenotype of GA-reactive T cells from the cerebrospinal fluid (CSF) and blood of five MS patients treated with GA for 3-36 months, and in three of these patients also before treatment. From the CSF of these patients, all 22 T cell lines generated before and all 38 T cell lines generated during treatment were GA-reactive. GA treatment induced a more pronounced anti-inflammatory profile of GA-reactive T cell lines from CSF than from blood. While GA-reactive T cell clones from CSF were restricted by either human leukocyte antigen (HLA) -DR or HLA-DP, only HLA-DR restricted GA-reactive T cell clones were detected in blood. No cross reactivity with myelin proteins was detected in GA-reactive T cell lines or clones from CSF. These results suggest that a selected subset of GA-reactive T cells are present in the intrathecal compartment, and support an anti-inflammatory mechanism of action for GA.
引用
收藏
页码:749 / 758
页数:10
相关论文
共 50 条
  • [1] Multiple sclerosis: Phenotype of cerebrospinal fluid T cells specific for glatiramer acetate
    Hestvik, Anne Lise K.
    Skorstad, Gjertrud
    Vartdal, Frode
    Holmoy, Trygve
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2007, 65 (06) : 599 - 599
  • [2] Multiple sclerosis: Phenotype of cerebrospinal fluid T cells specific for glatiramer acetate
    Holmoy, Trygve
    Skorstad, Gjertrud
    Hestvik, Anne Lise K.
    Vartdal, Frode
    NEUROLOGY, 2007, 68 (12) : A19 - A20
  • [4] Plovamer acetate, but not glatiramer acetate, induces an anti-inflammatory phenotype in human monocytes
    Tham, Chui-se
    Webb, Mike
    Crook, Kenneth
    Boschert, Ursula
    JOURNAL OF NEUROIMMUNOLOGY, 2014, 275 (1-2) : 84 - 84
  • [5] Phenotype of cerebrospinal fluid T cells induced by glatiramer acetate
    Holmoy, Trygve
    Vartdal, Frode
    Skorstad, Gjertrud
    Price, David A.
    Hestvik, Anne Lise K.
    MULTIPLE SCLEROSIS, 2008, 14 : S126 - S126
  • [6] The percentage of T regulatory and anti-inflammatory monocytes cells in multiple sclerosis patients is restored and maintained at high-level by glatiramer acetate
    Spadaro, M.
    Montarolo, F.
    Perga, S.
    Bertolotto, A.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 788 - 789
  • [7] In vitro evidence that subcutaneous administration of glatiramer acetate induces hyporesponsive T cells in patients with multiple sclerosis
    Schmied, M
    Duda, PW
    Krieger, JI
    Trollmo, C
    Hafler, DA
    CLINICAL IMMUNOLOGY, 2003, 106 (03) : 163 - 174
  • [8] The therapeutic effect of glatiramer acetate in a murine model of inflammatory bowel disease is mediated by anti-inflammatory T-cells
    Aharoni, Rina
    Sonego, Hagar
    Brennerb, Ori
    Eiam, Raya
    Arnon, Ruth
    IMMUNOLOGY LETTERS, 2007, 112 (02) : 110 - 119
  • [9] Glatiramer acetate for multiple sclerosis
    La Mantia, Loredana
    Munari, Luca M.
    Lovati, Roberta
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (05):
  • [10] Biological activity of glatiramer acetate on Treg and anti-inflammatory monocytes persists for more than 10 years in responder multiple sclerosis patients
    Spadaro, Michela
    Montarolo, Francesca
    Perga, Simona
    Martire, Serena
    Brescia, Federica
    Malucchi, Simona
    Bertolotto, Antonio
    CLINICAL IMMUNOLOGY, 2017, 181 : 83 - 88